| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
NRP1 antagonist 1 selectively targets Neuropilin-1 (NRP1), a transmembrane co-receptor for VEGF-A165 and semaphorins. NRP1 is involved in tumor angiogenesis, progression, and immune regulation. The antagonist blocks the binding of VEGF to NRP1, inhibiting downstream signaling.
|
|---|---|
| ln Vitro |
NRP1 antagonist 1 demonstrates potent inhibition with an IC50 of 19.1 microM in binding assays. This activity effectively blocks the VEGF-NRP interaction, which is crucial for pathological angiogenesis in cancer. It exhibits non-peptide structural characteristics, offering advantages for potential oral bioavailability.
|
| ln Vivo |
Dedicated in vivo efficacy studies for NRP1 antagonist 1 are not extensively documented in standard profiles. As a research tool for NRP1, it has shown potential in reducing angiogenesis in preclinical models, but detailed animal study data are not widely available.
|
| Enzyme Assay |
The binding affinity of NRP1 antagonist 1 to the b1 domain of NRP1 is measured using a competitive ELISA or Surface Plasmon Resonance (SPR). The compound is incubated with immobilized NRP1 protein and a labeled VEGF-A165 ligand. The IC50 is calculated based on inhibition of the ligand-receptor interaction.
|
| Cell Assay |
Endothelial cells (e.g., HUVECs) are cultured and treated with NRP1 antagonist 1 in the presence of VEGF-A165. Functional angiogenesis assays such as cell migration (wound healing) and tube formation on Matrigel are performed. Inhibition of these processes confirms functional antagonism.
|
| Animal Protocol |
Dedicated in vivo protocols for NRP1 antagonist 1 are not well-documented. A standard protocol for a related NRP1 antagonist would involve subcutaneous xenograft tumor models in nude mice. The compound would be administered via intraperitoneal injection. Tumor growth and microvessel density would be monitored.
|
| ADME/Pharmacokinetics |
Detailed PK parameters for NRP1 antagonist 1 are not extensively documented. As a non-peptide small molecule with a molecular weight of 450.58 g/mol, it may exhibit improved stability and permeability compared to peptide-based NRP1 antagonists, but comprehensive ADME data are not publicly reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for NRP1 antagonist 1 are not available in standard profiles. As a research chemical not intended for clinical development, comprehensive toxicology studies have not been performed. Standard laboratory safety precautions apply.
|
| References | |
| Additional Infomation |
NRP1 antagonist 1 is identified as compound 12a and is classified as a non-peptide antagonist, which is an advantage over peptide-based agents for potential therapeutic development. It is strictly a research tool for studying Neuropilin-1 biology in cancer and angiogenesis.
|
| Molecular Formula |
C22H22N6OS2
|
|---|---|
| Molecular Weight |
450.579680919647
|
| Exact Mass |
450.129
|
| CAS # |
2569598-01-0
|
| PubChem CID |
156017804
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
590
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(NC1=NN=C(CC)S1)(=O)CSC1N(C2=CC=CC(C)=C2)C(C2=CC=C(C)C=C2)=NN=1
|
| InChi Key |
OWXHHEPYWMHKHC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H22N6OS2/c1-4-19-24-26-21(31-19)23-18(29)13-30-22-27-25-20(16-10-8-14(2)9-11-16)28(22)17-7-5-6-15(3)12-17/h5-12H,4,13H2,1-3H3,(H,23,26,29)
|
| Chemical Name |
N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-[[4-(3-methylphenyl)-5-(4-methylphenyl)-1,2,4-triazol-3-yl]sulfanyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~184.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2194 mL | 11.0968 mL | 22.1936 mL | |
| 5 mM | 0.4439 mL | 2.2194 mL | 4.4387 mL | |
| 10 mM | 0.2219 mL | 1.1097 mL | 2.2194 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
